Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study

References

• European Centre for Disease Prevention and Control. Overview of EU/EEA country recommendations on COVID-19 vaccination with Vaxzevria, and a scoping review of evidence to guide decision-making. Stockholm: European Centre for Disease Prevention and Control; 2021. [accessed 2021 September 27]. https://www.ecdc.europa.eu/sites/default/files/documents/Overview%20EU%20EEA%20country%20recommendations%20on%20COVID-19%20vaccination%20Vaxzevria%20and%20scoping%20review%20of%20evidence.pdf.
   Google Scholar
• Normark J, Vikström L, Gwon YD, Persson IL, Edin A, Björsell T, Dernstedt A, Christ W, Tevell S, Evander M, et al. Heterologous ChAdOx1 nCoV-19 and mRNA-1273 vaccination. N Engl J Med. 2021 Sep 9;385(11):1049–10. doi:10.1056/NEJMc2110716.
   PubMed Web of Science ®Google Scholar
• Schmidt T, Klemis V, Schub D, Mihm J, Hielscher F, Marx S, Abu-Omar A, Ziegler L, Guckelmus C, Urschel R, et al. Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination. Nat Med. 2021 Sep;27(9):1530–35. doi:10.1038/s41591-021-01464-w.
   PubMed Web of Science ®Google Scholar
• Borobia AM, Carcas AJ, Pérez-Olmeda M, Castaño L, Bertran MJ, García-Pérez J, Campins M, Portolés A, González-Pérez M, García Morales MT, et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet. 2021 Jul 10;398(10295):121–30. doi:10.1016/S0140-6736(21)01420-3.
   PubMed Web of Science ®Google Scholar
• Liu X, Shaw RH, Stuart ASV, Greenland M, Aley PK, Andrews NJ, Cameron JC, Charlton S, Clutterbuck EA, Collins AM, et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet. 2021 Sep 4;398(10303):856–69. doi:10.1016/S0140-6736(21)01694-9.
   PubMed Web of Science ®Google Scholar
• Hammerschmidt SI, Bosnjak B, Bernhardt G, Friedrichsen M, Ravens I, Dopfer-Jablonka A, Hoffmann M, Pöhlmann S, Behrens GMN, Förster R. Neutralization of the SARS-CoV-2 Delta variant after heterologous and homologous BNT162b2 or ChAdOx1 nCoV-19 vaccination. Cell Mol Immunol. 2021 Oct;18(10):2455–56. doi:10.1038/s41423-021-00755-z.
   PubMed Web of Science ®Google Scholar
• Kant R, Dwivedi G, Zaman K, Sahay RR, Sapkal G, Kaushal H, Nyayanit DA, Yadav PD, Deshpande G, Singh R. Serendipitous COVID-19 vaccine-mix in Uttar Pradesh, India: safety and immunogenicity assessment of a heterologous regime. medRxiv preprint. 2021 Aug 13. doi:10.1101/2021.08.06.21261716.
   Google Scholar
• Jingxin L, Hou L, Guo X, Jin P, Wu S, Zhu J, Pan H, Wang X, Song Z, Wan J. Heterologous prime-boost immunization with CoronaVac and Convidecia. medRxiv. 2021 Sep 6. doi:10.1101/2021.09.03.21263062.
   Google Scholar
• Tanakasempipat P, Thepgumpanat P. Thailand sticks with Sinovac vaccine after cases of ‘stroke-like’ side effects. Reuters. 2021 Apr 21 [accessed 2021 Jun 23]. https://www.reuters.com/world/asia-pacific/thailand-sticks-with-sinovac-vaccine-after-cases-stroke-like-side-effects-2021-04-21.
   Google Scholar
• World Health Organization. Immunization stress-related response: a manual for program managers and health professionals to prevent, identify and respond to stress-related responses following immunization. Geneva: World Health Organization; 2019. [accessed 2021 September 11]. https://apps.who.int/iris/handle/10665/330277.
   Google Scholar
• Wanlapakorn W, Suntronwong N, Phowatthanasathian H, Yorsang R, Thongmee T, Vichaiwattana P, Auphimai C, Wongsrisang L, Klinfueng S, Sudhinaraset N, et al. Immunogenicity of heterologous prime/booster-inactivated and adenoviral-vectored COVID-19 vaccine: real-world data. Res Sq. 2021 Sep 10. doi:10.21203/rs.3.rs-785693/v2.
   Google Scholar
• Johnson K. In first, Thailand to mix Sinovac, AstraZeneca vaccine doses. 2021 July 12 [accessed 2021 Jul 16]. https://www.reuters.com/world/asia-pacific/thailand-starts-tighter-coronavirus-lockdown-around-capital-2021-07-12.
   Google Scholar
• World Health Organization. Recommendation for an emergency use listing of COVID-19 vaccine (Vero cell), inactivated submitted by Sinovac. Geneva: World Health Organization; 2021. [accessed 2021 Jul 18]. https://extranet.who.int/pqweb/key-resources/documents/sinovac-tag-reportcoronavactmpublished28jun2021.
   Google Scholar
• European Medicines Agency. COVID-19 vaccine AstraZeneca. Amsterdam: European Medicine Agency; 2021. [accessed 2021 Jul 16]. https://www.ema.europa.eu/en/documents/product-information/covid-19-vaccine-astrazeneca-product-information-approved-chmp-29-january-2021-pending-endorsement_en.pdf.
   Google Scholar
• Shaw RH, Stuart A, Greenland M, Liu X, Nguyen Van-Tam JS, Snape MD, Com-COV Study Group. Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data. Lancet. 2021 May 29;397(10289):2043–46. doi:10.1016/S0140-6736(21)01115-6.
   PubMed Web of Science ®Google Scholar
• Fadlyana E, Rusmil K, Tarigan R, Rahmadi AR, Prodjosoewojo S, Sofiatin Y, Khrisna CV, Sari RM, Setyaningsih L, Surachman F. A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: an interim analysis in Indonesia. Vaccine. 2021 Oct 22;39(44):6520–28. doi:10.1016/j.vaccine.2021.09.052.
   PubMed Web of Science ®Google Scholar
• Tanriover MD, Doğanay HL, Akova M, Güner HR, Azap A, Akhan S, Köse Ş, Erdinç FŞ, Akalın EH, Tabak ÖF, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021 Jul 17;398(10296):213–22. doi:10.1016/S0140-6736(21)01429-X.
   PubMed Web of Science ®Google Scholar
• Corbett KS, Nason MC, Flach B, Gagne M, O’Connell S, Johnston TS, Shah SN, Edara VV, Floyd K, Lai L, et al. Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. Science. 2021 Sep 17;373(6561):eabj0299. doi:10.1126/science.abj0299.
   PubMed Web of Science ®Google Scholar
• Feng S, Phillips DJ, White T, Sayal H, Aley PK, Bibi S, Dold C, Fuskova M, Gilbert SC, Hirsch I, et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med. 2021 Sep 29;27:2032–40. doi:10.1038/s41591-021-01540-1.
   PubMed Web of Science ®Google Scholar
• Barros-Martins J, Hammerschmidt SI, Cossmann A, Odak I, Stankov MV, Morillas Ramos G, Dopfer-Jablonka A, Heidemann A, Ritter C, Friedrichsen M, et al. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nat Med. 2021 Sep;27(9):1525–29. doi:10.1038/s41591-021-01449-9.
   PubMed Web of Science ®Google Scholar
• Dimeglio C, Herin F, Da-Silva I, Jougla I, Pradere C, Porcheron M, Martin-Blondel G, Chapuy-Regaud S, Izopet J. Heterologous ChAdOx1-S/BNT162b2 vaccination: neutralizing antibody response to SARS-CoV-2. Clin Infect Dis. 2021 Aug 12. ciab705. Epub ahead of print. doi:10.1093/cid/ciab705.
   Google Scholar
• Benjamanukul S, Traiyan S, Yorsaeng R, Vichaiwattana P, Sudhinaraset N, Wanlapakorn N, Poovorawan Y. Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers. J Med Virol. 2021. doi:10.1002/jmv.27458.
   PubMedGoogle Scholar
• Hillus D, Schwarz T, Tober-Lau P, Vanshylla K, Hastor H, Thibeault C, Jentzsch S, Helbig ET, Lippert LJ, Tscheak P, et al. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. Lancet Respir Med. 2021 Aug 12: S2213-2600(21)00357-X. doi:10.1016/S2213-2600(21)00357-X.
   Google Scholar
• Rahman MS, Islam MR, Alam ASMRU, Islam I, Hoque MN, Akter S, Rahaman MM, Sultana M, Hossain MA. Evolutionary dynamics of SARS-CoV-2 nucleocapsid protein and its consequences. J Med Virol. 2021 Apr;93(4):2177–95. doi:10.1002/jmv.26626.
   PubMed Web of Science ®Google Scholar
• Chansaenroj J, Yorsaeng R, Posuwan N, Puenpa J, Wanlapakorn N, Sudihinaraset N, Sripramote M, Chalongviriyalert P, Jirajariyavej S, Kiatpanabhikul P. Long-term specific IgG response to SARS-CoV-2 nucleocapsid protein in recovered COVID-19 patients. Res Sq. 2021 Jul 1. doi:10.21203/rs.3.rs-608525/v1.
   Google Scholar
• Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, Li Y, Zhu L, Wang N, Lv Z, et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020 Jul 3;369(6499):77–81. doi:10.1126/science.abc1932.
   PubMed Web of Science ®Google Scholar
• Wisnewski AV, Campillo Luna J, Redlich CA. Human IgG and IgA responses to COVID-19 mRNA vaccines. PLoS One. 2021 Jun 16;16(6):e0249499. doi:10.1371/journal.pone.
   PubMed Web of Science ®Google Scholar
• Zurac S, Nichita L, Mateescu B, Mogodici C, Bastian A, Popp C, Cioplea M, Socoliu C, Constantin C, Neagu M. COVID‑19 vaccination and IgG and IgA antibody dynamics in healthcare workers. Mol Med Rep. 2021 Aug;24(2):578. doi:10.3892/mmr.2021.12217.
   PubMed Web of Science ®Google Scholar
• Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M, Cho A, Jankovic M, Schaefer-Babajew D, Oliveira TY, et al. Evolution of antibody immunity to SARS-CoV-2. bioRxiv [Preprint]. 2021 Jan 4. 2020.11.03.367391. Update in: Nature. 2021 Mar;591(7851):639-644. doi:10.1101/2020.11.03.367391.
   Google Scholar
• Yorsaeng R, Suntronwong N, Phowatthanasathian H, Assawakosri S, Kanokudom S, Thongmee T, Vichaiwattana P, Auphimai C, Wongsrisang L, Srimuan D, et al. Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults. Vaccine. 2021:S0264-410X(21)01560–7. doi:10.1016/j.vaccine.2021.11.083.
   PubMedGoogle Scholar
• Sterlin D, Mathian A, Miyara M, Mohr A, Anna F, Claër L, Quentric P, Fadlallah J, Devilliers H, Ghillani P, et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci Transl Med. 2021 Jan 20;13(577):eabd2223. doi:10.1126/scitranslmed.abd2223.
   PubMed Web of Science ®Google Scholar
• Bueno SM, Abarca K, González PA, Gálvez NMS, Soto JA, Duarte LF, Schultz BM, Pacheco GA, González LA, Vázquez Y, et al. Safety and Immunogenicity of an inactivated SARS-CoV-2 vaccine in a subgroup of healthy adults in Chile. Clin Infect Dis. 2021 Sep 19:ciab823. doi:10.1093/cid/ciab823.
   Web of Science ®Google Scholar
• Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, Baum A, Pascal K, Quandt J, Maurus D, et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. 2020 Oct;586(7830):594–99. doi:10.1038/s41586-020-2814-7.
   PubMed Web of Science ®Google Scholar
• Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, Wu SP, Wang BS, Wang Z, Wang L, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020 Jun 13;395(10240):1845–54. doi:10.1016/S0140-6736(20)31208-3.
   PubMed Web of Science ®Google Scholar
• Jaganathan S, Stieber F, Rao SN, Nikolayevskyy V, Manissero D, Allen N, Boyle J, Howard J. Preliminary evaluation of QuantiFERON SARS-CoV-2 and QIAreach anti-SARS-CoV-2 total test in recently vaccinated individuals. Infect Dis Ther. 2021 Aug;25:1–12. doi:10.1007/s40121-021-00521-8.
   Google Scholar
• Zuo J, Dowell AC, Pearce H, Verma K, Long HM, Begum J, Aiano F, Amin-Chowdhury Z, Hoschler K, Brooks T, et al. Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection. Nat Immunol. 2021 May;22(5):620–26. doi:10.1038/s41590-021-00902-8.
   PubMed Web of Science ®Google Scholar
• Ng OW, Chia A, Tan AT, Jadi RS, Leong HN, Bertoletti A, Tan YJ. Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection. Vaccine. 2016 Apr 12;34(17):2008–14. doi:10.1016/j.vaccine.2016.02.063.
   PubMed Web of Science ®Google Scholar
• Hunsawong T, Fernandez S, Buathong R, Khadthasrima N, Rungrojchareonkit K, Lohachanakul J, Suthangkornkul R, Tayong K, Huang AT, Klungthong C, et al. Limited and short-lasting virus neutralizing titers induced by inactivated SARS-CoV-2 vaccine. Emerg Infect Dis. 2021 Oct 8;27(12):3178–80. doi:10.3201/eid2712.211772.
   PubMed Web of Science ®Google Scholar
• Thepgumpanat P, Setboonsarng C, Wongcha-um P. Thailand cites positive results from Sinovac-AstraZeneca vaccine formula. Reuters. 2021 Sep 2 [accessed 2021 Oct 6]. https://www.reuters.com/world/asia-pacific/thailand-cites-positive-results-sinovac-astrazeneca-vaccine-formula-2021-09-02.
   Google Scholar